Management of pediatric pemphigus vulgaris with rituximab: A case report and review of the literature
Pemphigus vulgaris (PV), an acquired autoimmune bullous disease, is caused by autoantibodies targeting desmosomal proteins in the skin and mucous membranes. Recent data from the adult PV population supports the use of rituximab, a chimeric anti‐CD20 IgG1 antibody, as a primary treatment strategy, bu...
Gespeichert in:
| Veröffentlicht in: | Pediatric dermatology 2022-11, Vol.39 (6), p.960-966 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 966 |
|---|---|
| container_issue | 6 |
| container_start_page | 960 |
| container_title | Pediatric dermatology |
| container_volume | 39 |
| creator | Mistry, Bhavik Dipak Leis, Maria Lee, David Michael Levy, Rebecca |
| description | Pemphigus vulgaris (PV), an acquired autoimmune bullous disease, is caused by autoantibodies targeting desmosomal proteins in the skin and mucous membranes. Recent data from the adult PV population supports the use of rituximab, a chimeric anti‐CD20 IgG1 antibody, as a primary treatment strategy, but limited data exist regarding treatment in the pediatric population. We report the case of a 13‐year‐old male with PV treated successfully with systemic corticosteroids and rituximab, and review the literature supporting the treatment of pediatric PV with rituximab. |
| doi_str_mv | 10.1111/pde.15095 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2694417867</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2740453928</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3305-2d0f29fd748fcc4a17b77a993839ebbdc1db17939ee32c83e7448da1b3162e1c3</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0EEqWw4A8ssYFFWjt24oRdVcpDAsEC1pbjTFpXeWE7Lf17XMoKidnMHenM1cxF6JKSCQ017UuY0ITkyREa0SROIsoFOUYjIlgaZYSnp-jMuTUhJEtTOkLwolq1hAZaj7sK91Aa5a3RQTX9yiwHhzdDvVTWOLw1foWt8cOXaVRxi2dYKwfYQt9Zj1VbBrkxsN0b-RXg2niwyg8WztFJpWoHF799jD7uF-_zx-j59eFpPnuONGMkieKSVHFelYJnldZcUVEIofKcZSyHoig1LQsq8jAAi3XGQHCelYoWjKYxUM3G6Prg29vucwDnZWOchrpWLXSDk3Gac05FloqAXv1B191g23CdjAUnPGF5nAXq5kBp2zlnoZK9Dc_bnaRE7gOXIXD5E3hgpwd2a2rY_Q_Kt7vFYeMbzkSCag</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2740453928</pqid></control><display><type>article</type><title>Management of pediatric pemphigus vulgaris with rituximab: A case report and review of the literature</title><source>Access via Wiley Online Library</source><creator>Mistry, Bhavik Dipak ; Leis, Maria ; Lee, David Michael ; Levy, Rebecca</creator><creatorcontrib>Mistry, Bhavik Dipak ; Leis, Maria ; Lee, David Michael ; Levy, Rebecca</creatorcontrib><description>Pemphigus vulgaris (PV), an acquired autoimmune bullous disease, is caused by autoantibodies targeting desmosomal proteins in the skin and mucous membranes. Recent data from the adult PV population supports the use of rituximab, a chimeric anti‐CD20 IgG1 antibody, as a primary treatment strategy, but limited data exist regarding treatment in the pediatric population. We report the case of a 13‐year‐old male with PV treated successfully with systemic corticosteroids and rituximab, and review the literature supporting the treatment of pediatric PV with rituximab.</description><identifier>ISSN: 0736-8046</identifier><identifier>EISSN: 1525-1470</identifier><identifier>DOI: 10.1111/pde.15095</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc</publisher><subject>Autoantibodies ; Autoimmune diseases ; Bullous diseases ; Case reports ; CD20 antigen ; Corticosteroids ; Immunoglobulin G ; Immunotherapy ; Literature reviews ; management ; Monoclonal antibodies ; pediatric pemphigus vulgaris ; Pediatrics ; Pemphigus ; Rituximab ; Skin diseases ; topical corticosteroids ; treatment</subject><ispartof>Pediatric dermatology, 2022-11, Vol.39 (6), p.960-966</ispartof><rights>2022 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3305-2d0f29fd748fcc4a17b77a993839ebbdc1db17939ee32c83e7448da1b3162e1c3</citedby><cites>FETCH-LOGICAL-c3305-2d0f29fd748fcc4a17b77a993839ebbdc1db17939ee32c83e7448da1b3162e1c3</cites><orcidid>0000-0001-7284-3128</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fpde.15095$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fpde.15095$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids></links><search><creatorcontrib>Mistry, Bhavik Dipak</creatorcontrib><creatorcontrib>Leis, Maria</creatorcontrib><creatorcontrib>Lee, David Michael</creatorcontrib><creatorcontrib>Levy, Rebecca</creatorcontrib><title>Management of pediatric pemphigus vulgaris with rituximab: A case report and review of the literature</title><title>Pediatric dermatology</title><description>Pemphigus vulgaris (PV), an acquired autoimmune bullous disease, is caused by autoantibodies targeting desmosomal proteins in the skin and mucous membranes. Recent data from the adult PV population supports the use of rituximab, a chimeric anti‐CD20 IgG1 antibody, as a primary treatment strategy, but limited data exist regarding treatment in the pediatric population. We report the case of a 13‐year‐old male with PV treated successfully with systemic corticosteroids and rituximab, and review the literature supporting the treatment of pediatric PV with rituximab.</description><subject>Autoantibodies</subject><subject>Autoimmune diseases</subject><subject>Bullous diseases</subject><subject>Case reports</subject><subject>CD20 antigen</subject><subject>Corticosteroids</subject><subject>Immunoglobulin G</subject><subject>Immunotherapy</subject><subject>Literature reviews</subject><subject>management</subject><subject>Monoclonal antibodies</subject><subject>pediatric pemphigus vulgaris</subject><subject>Pediatrics</subject><subject>Pemphigus</subject><subject>Rituximab</subject><subject>Skin diseases</subject><subject>topical corticosteroids</subject><subject>treatment</subject><issn>0736-8046</issn><issn>1525-1470</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kMtOwzAQRS0EEqWw4A8ssYFFWjt24oRdVcpDAsEC1pbjTFpXeWE7Lf17XMoKidnMHenM1cxF6JKSCQ017UuY0ITkyREa0SROIsoFOUYjIlgaZYSnp-jMuTUhJEtTOkLwolq1hAZaj7sK91Aa5a3RQTX9yiwHhzdDvVTWOLw1foWt8cOXaVRxi2dYKwfYQt9Zj1VbBrkxsN0b-RXg2niwyg8WztFJpWoHF799jD7uF-_zx-j59eFpPnuONGMkieKSVHFelYJnldZcUVEIofKcZSyHoig1LQsq8jAAi3XGQHCelYoWjKYxUM3G6Prg29vucwDnZWOchrpWLXSDk3Gac05FloqAXv1B191g23CdjAUnPGF5nAXq5kBp2zlnoZK9Dc_bnaRE7gOXIXD5E3hgpwd2a2rY_Q_Kt7vFYeMbzkSCag</recordid><startdate>202211</startdate><enddate>202211</enddate><creator>Mistry, Bhavik Dipak</creator><creator>Leis, Maria</creator><creator>Lee, David Michael</creator><creator>Levy, Rebecca</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7284-3128</orcidid></search><sort><creationdate>202211</creationdate><title>Management of pediatric pemphigus vulgaris with rituximab: A case report and review of the literature</title><author>Mistry, Bhavik Dipak ; Leis, Maria ; Lee, David Michael ; Levy, Rebecca</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3305-2d0f29fd748fcc4a17b77a993839ebbdc1db17939ee32c83e7448da1b3162e1c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Autoantibodies</topic><topic>Autoimmune diseases</topic><topic>Bullous diseases</topic><topic>Case reports</topic><topic>CD20 antigen</topic><topic>Corticosteroids</topic><topic>Immunoglobulin G</topic><topic>Immunotherapy</topic><topic>Literature reviews</topic><topic>management</topic><topic>Monoclonal antibodies</topic><topic>pediatric pemphigus vulgaris</topic><topic>Pediatrics</topic><topic>Pemphigus</topic><topic>Rituximab</topic><topic>Skin diseases</topic><topic>topical corticosteroids</topic><topic>treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mistry, Bhavik Dipak</creatorcontrib><creatorcontrib>Leis, Maria</creatorcontrib><creatorcontrib>Lee, David Michael</creatorcontrib><creatorcontrib>Levy, Rebecca</creatorcontrib><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mistry, Bhavik Dipak</au><au>Leis, Maria</au><au>Lee, David Michael</au><au>Levy, Rebecca</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of pediatric pemphigus vulgaris with rituximab: A case report and review of the literature</atitle><jtitle>Pediatric dermatology</jtitle><date>2022-11</date><risdate>2022</risdate><volume>39</volume><issue>6</issue><spage>960</spage><epage>966</epage><pages>960-966</pages><issn>0736-8046</issn><eissn>1525-1470</eissn><abstract>Pemphigus vulgaris (PV), an acquired autoimmune bullous disease, is caused by autoantibodies targeting desmosomal proteins in the skin and mucous membranes. Recent data from the adult PV population supports the use of rituximab, a chimeric anti‐CD20 IgG1 antibody, as a primary treatment strategy, but limited data exist regarding treatment in the pediatric population. We report the case of a 13‐year‐old male with PV treated successfully with systemic corticosteroids and rituximab, and review the literature supporting the treatment of pediatric PV with rituximab.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1111/pde.15095</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-7284-3128</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0736-8046 |
| ispartof | Pediatric dermatology, 2022-11, Vol.39 (6), p.960-966 |
| issn | 0736-8046 1525-1470 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2694417867 |
| source | Access via Wiley Online Library |
| subjects | Autoantibodies Autoimmune diseases Bullous diseases Case reports CD20 antigen Corticosteroids Immunoglobulin G Immunotherapy Literature reviews management Monoclonal antibodies pediatric pemphigus vulgaris Pediatrics Pemphigus Rituximab Skin diseases topical corticosteroids treatment |
| title | Management of pediatric pemphigus vulgaris with rituximab: A case report and review of the literature |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T21%3A04%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20pediatric%20pemphigus%20vulgaris%20with%20rituximab:%20A%20case%20report%20and%20review%20of%20the%20literature&rft.jtitle=Pediatric%20dermatology&rft.au=Mistry,%20Bhavik%20Dipak&rft.date=2022-11&rft.volume=39&rft.issue=6&rft.spage=960&rft.epage=966&rft.pages=960-966&rft.issn=0736-8046&rft.eissn=1525-1470&rft_id=info:doi/10.1111/pde.15095&rft_dat=%3Cproquest_cross%3E2740453928%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2740453928&rft_id=info:pmid/&rfr_iscdi=true |